Alaunos Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing immuno-oncology platforms that utilize cell- and gene-based therapies to treat patients with cancer. Co.'s primary platform is referred to as Sleeping Beauty and is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that is intended to stably engineer T cells outside of the body for subsequent infusion. Co.'s second platform is referred to as Controlled IL-12 and is designed to stimulate expression of interleukin 12, a master regulator of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. The TCRT stock yearly return is shown above.
The yearly return on the TCRT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCRT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|